Appendices

Table of Contents

pendix 1: Model Description – MISCAN-Colon	1
General Model Structure	1
ntegrating Modules	3
References	8
pendix 2: Calibration results of the MISCAN-Colon microsimulation model to th	ie
rwegian setting	9
igure 1: Calibration results: Observed and model-predicted colorectal cancer incidence ge and stage distribution for Norway	•
pendix 3: Validation of the MISCAN-Colon microsimulation model against the l	
moidoscopy study	
Methods	
/alidation results	
Table 1. Hazard ratios: 14-16 years follow-up interventions effects of the NORCCAP trial 15% confidence intervals for these effects and MISCAN- Colon predictions of these effects and MISCAP trial results were derived from Holme et al. 2018 ²	cts.a
References	
pendix 4: MISCAN-Colon predictions with 15 year follow-up stratified for color	
ncer risk, age and gender	
igure 1: MISCAN-Colon predictions of colorectal cancer mortality and incidence reductions of incidence reductions of incidence reductions in the sigmoid of incidence reductions is a serific of incidence reductions of incid	by CRC
igure 2: MISCAN-Colon predictions of complications per 1000 individuals, using FIT, flexigmoidoscopy or colonoscopy. Results are stratified by CRC risk and age. Individuals we ollowed-up during 15 years.	ere
ables: MISCAN-Colon predictions stratified for colorectal cancer risk, age and sex	22
Table 1: MISCAN-Colon predictions of benefits and harms of various screening strategie ollow-up period of 15 years for men, aged 50-54, stratified by risk	_
Table 2: MISCAN-Colon predictions of benefits and harms of various screening strategie ollow-up period of 15 years for men, aged 55-59, stratified by risk	•
Table 3: MISCAN-Colon predictions of benefits and harms of various screening strategie ollow-up period of 15 years for men, aged 60-64, stratified by risk	_
Table 4: MISCAN-Colon predictions of benefits and harms of various screening strategie ollow-up period of 15 years for men, aged 65-69, stratified by risk	_

Table 5: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 70-74, stratified by risk	
Table 6: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 75-79, stratified by risk	
Table 7: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 50-54, stratified by risk	
Table 8: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 55-59, stratified by risk	
Table 9: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 60-64, stratified by risk	
Table 10: MISCAN-Colon predictions of benefits and harms of various screening strategies during follow-up period of 15 years for women, aged 65-69, stratified by risk	
Table 11: MISCAN-Colon predictions of benefits and harms of various screening strategies during follow-up period of 15 years for women, aged 70-74, stratified by risk	
Table 12: MISCAN-Colon predictions of benefits and harms of various screening strategies during follow-up period of 15 years for women, aged 75-79, stratified by risk	
Appendix 5: MISCAN-Colon predictions with lifetime year follow-up stratified for colorect cancer risk, age and gender	
Figure 1: MISCAN-Colon predictions of colorectal cancer mortality reduction, colorectal cancer incidence reduction per 1000 individuals, using FIT, flexible sigmoidoscopy or colonoscopy. Resul were stratified for CRC risk. Individuals were followed for a lifetime.	
Figure 2: MISCAN-Colon predictions of colorectal cancer mortality reduction, colorectal cancer incidence reduction per 1000 individuals, using FIT, flexible sigmoidoscopy or colonoscopy. Resul were stratified for CRC risk and age. Individuals were followed for a lifetime	

Appendix 1: Model Description - MISCAN-Colon

General Model Structure

MISCAN-Colon is a stochastic microsimulation model for colorectal cancer (CRC) programmed in Delphi (Borland Software Corporation, Scotts Valley, California, United States). It can be used to explain and predict trends in CRC incidence and mortality and to quantify the effects and costs of primary prevention of CRC, screening for CRC, and surveillance after polypectomy.

The term 'microsimulation' implies that individuals are moved through the model one at a time, rather than as proportions of a cohort. This allows future state transitions to depend on past transitions, giving the model a 'memory'. Furthermore, unlike most traditional Markov models, MISCAN-Colon does not use yearly transition probabilities; instead it generates durations in states, thereby increasing model flexibility and computational performance. The term 'stochastic' implies that the model simulates sequences of events by drawing from distributions of probabilities/ durations, rather than using fixed values. Hence, the results of the model are subject to random variation.

MISCAN-Colon consists of 3 modules: a demography module, natural history module, and screening module.

a. The Demography Module

Using birth- and life-tables representative for the population under consideration, MISCAN-Colon draws a date of birth and a date of non-CRC death for each individual simulated. In MISCAN-Colon the maximum age an individual can achieve is exactly 100 years.

b. The Natural History Module

Transitions

As each simulated person ages, one or more adenomas may develop (Model Appendix Figure 1). These adenomas can be either progressive or non-progressive. Both progressive and non-progressive adenomas can grow in size from small (≤5mm), to medium (6-9mm), to large (≥10mm); however, only progressive adenomas can develop into preclinical cancer. A preclinical cancer may

progress through stages I to IV; however, during each stage CRC may be diagnosed because of symptoms. After clinical diagnosis, the survival depends on the stage of the cancer. For individuals with synchronous CRCs at time of diagnosis, the survival of the most advanced cancer is used. The date of death for individuals with CRC is set to the earliest simulated death (either due to CRC or due to another cause (see: 'The demography module')).

Transition Probabilities and Durations in States

An individual's risk of developing adenomas depends on the individual's age and a personal risk index. As a result of the latter most individuals develop no adenomas, whilst some develop many. We assumed that the distribution of adenomas over the colon and rectum equals the distribution of cancers in Norway during the NORCCAP trial, before the introduction of screening (between 1999 and 2011). Data was provided by the Norwegian Cancer Registry. The age-specific onset of adenomas and the dispersion of the personal risk index were calibrated to data on the prevalence and multiplicity distribution of adenomas as observed in autopsy studies (Model Appendix Figure 2).(2-11) The age-specific probability of adenoma-progressivity and the age- and localization-specific transition probabilities between preclinical cancer stages and between preclinical and clinical cancer stages were simultaneously calibrated to data on the age-, stage-, and localization-specific incidence of CRC in Norway during the NORCCAP trial, before the introduction of screening (between 1999 and 2011) (Model Appendix Figure 3). Data was provided by the Norwegian Cancer Registry.

The average durations between the preclinical cancer stages were calibrated to the rates of screen-detected and interval cancers observed in randomized controlled trials evaluating screening using guaiac fecal occult blood tests.(12-14) This exercise has been described extensively in a publication by Lansdorp-Vogelaar and colleagues.(15) The average duration from the emergence of an adenoma (state 2) until progression into preclinical cancer (state 7) (i.e. the adenoma dwell-time) was calibrated to the rates of interval cancers (including surveillance detected cancers) observed in a randomized controlled trial evaluating once-only sigmoidoscopy screening (Model Appendix Figure 4). (16) We assumed an equal overall dwell-time for adenomas developing into CRC from a medium size (30% of all CRCs) and from a large size (70% of all CRCs). All durations in the adenoma and preclinical cancer phase were drawn from exponential distributions. Durations within the adenoma phase and within the preclinical cancer phase were assumed to be perfectly correlated (i.e. if a small

adenoma grows into a medium-sized adenoma rapidly, it will also grow into a large adenoma or develop into CRC rapidly); however, durations in the adenoma phase were assumed to be uncorrelated with durations in the preclinical cancer phase (i.e. a rapidly growing adenoma does not necessarily develop into a rapidly progressing cancer). The proportion of medium sized, non-progressive adenomas growing large and the average duration in duration in the medium size, non-progressive adenoma state (state 5) were calibrated to size-specific adenoma detection rates observed in a Dutch randomized controlled trial on colonoscopy screening (73% small adenomas, 15% medium sized adenomas, 12% large adenomas).(17)

c. The Screening Module

Screening will alter some of the simulated life histories: Some cancers will be prevented by the detection and removal of adenomas; other cancers will be detected in an earlier stage with a more favorable survival. As the stage-specific survival of screen-detected CRC as observed in randomized controlled trials on guaiac fecal occult blood testing was substantially more favorable than that of clinically detected CRC, even after correcting for lead-time bias, we assigned those screen-detected cancers that would have been clinically detected in the same stage the survival corresponding to a one stage less progressive cancer. Hence, a cancer screen-detected in stage II, that would also have been clinically diagnosed in stage II, is assigned the survival of a clinically diagnosed stage I cancer. The only exceptions were screen-detected stage IV cancers. These cancers were always assigned the survival of a clinically diagnosed stage IV cancer.


Besides modeling positive health effects of screening, we also model colonoscopy-related complications and over-diagnosis and over-treatment of CRC (i.e. the detection and treatment of cancers that would not have been diagnosed without screening).

Integrating Modules


The demography module generates a date of birth and a date of non-CRC death for each individual simulated, creating a life-history without adenomas or CRC. In Patient A in Model Appendix Figure 5, the natural history module generates an adenoma. This adenoma progresses into preclinical cancer, which is diagnosed because of symptoms in stage II and results in CRC death before non-

CRC death would have occurred. In the screening module a screening examination is simulated, indicated by the blue arrow. During this examination the adenoma is detected, and as a result both CRC and CRC death are prevented. Hence, in Patient A, screening prolongs life by the amount indicated by the green arrow. Patient B also develops an adenoma, and although this adenoma does progress into preclinical cancer, Patient B would never have been diagnosed with CRC in a scenario without screening (see life history 2). However, during the screening examination simulated in the screening module, again indicated by the blue arrow, CRC is screen-detected in stage I. Hence, in this patient screening results in over-diagnosis of CRC: It detects a cancer that would never have been diagnosed in a scenario without screening. Hence, screening does not prolong life, but it does result in additional LYs with CRC care (over-treatment) as indicated by the red arrow.

Model Appendix Figure 1. An Overview of the Natural History Module of MISCAN-Colon.




Model Appendix Figure 2. Adenoma Prevalence Simulated by MISCAN-Colon Versus Observed in Selected Autopsy Studies and corrected for country specific differences in CRC incidence (% of individuals with adenomas).*



*Observed results are only shown for the two largest studies on which the model has been calibrated.


MISCAN-Colon has additionally been calibrated to 8 other autopsy studies.


Model Appendix Figure 3. Norwegian CRC Incidence Observed during the NORCCAP trial period Versus Simulated by MISCAN-Colon; cases per 100,000 person years)



Solid line: simulated; error bars and point estimates: observed in Norway 1999-2011 (with 95% CI)


Model Appendix Figure 4. Distal CRC Incidence Observed in the Intervention Group of the UK Flexible Sigmoidoscopy Trial Versus Simulated by MISCAN-Colon (per year of follow-up (A), cumulative (B); cases per 100,000 person years).






Model Appendix Figure 5. Integrating Modules: Two example Patients.

PATIENT A: BENEFITTING FROM SCREENING



PATIENT B: OVER-DIAGNOSING CRC




References


- 1. Norwegian cancer registry at https://www.kreftregisteret.no/en/General/About-the-Cancer-Registry/ on 02 Jul 2018.
- 2. Arminski TC, McLean DW. Incidence and Distribution of Adenomatous Polyps of the Colon and Rectum Based on 1,000 Autopsy Examinations. Dis Colon Rectum. 1964;7:249-61.
- 3. Bombi JA. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer. 1988:61(7):1472-6.
- 4. Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg. 1963:157:223-6.
- 5. Clark JC, Collan Y, Eide TJ, Esteve J, Ewen S, Gibbs NM, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985;36(2):179-86.
- 6. Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut. 1992;33(11):1508-14.
- 7. Johannsen LG, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol. 1989;24(7):799-806.
- 8. L B. Polyps of the colon and rectum. Dis Colon Rectum. 1961;4:249-61.
- 9. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer. 1979;43(5):1847-57.
- 10. Vain MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer. 1982;49(4):819-25.
- 11. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982;23(10):835-42.
- 12. Hardcastle JD, Armitage NC, Chamberlain J, Amar SS, James PD, Balfour TW. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer. 1986;58(2):397-403.
- 13. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-71.
- 14. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434-7.
- 15. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer. 2009;115(11):2410-9.
- 16. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624-33.
- 17. Stoop EM, de Haan MC, de Wijkerslooth TR, Bossuyt PM, van Ballegooijen M, Nio CY, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol. 2012;13(1):55-64.

Appendix 2: Calibration results of the MISCAN-Colon microsimulation model to the Norwegian setting


Figure 1: Calibration results: Observed and model-predicted colorectal cancer incidence rates by age and stage distribution for Norway


a. Calibration results MISCAN-Colon female model







b. Calibration results MISCAN-Colon male model





c. Calibration results MISCAN-Colon combined model





Appendix 3: Validation of the MISCAN-Colon microsimulation model against the NORCCAP sigmoidoscopy study

Methods

We used MISCAN-Colon to simulate NORCCAP trial outcomes and compared predictions with those observed according to the same methodology as previously described.¹ Primary validation targets were relative overall and distal CRC incidence reduction and mortality reduction observed by Holme et al.,² who described the 15-year follow-up results of the NORCCAP trial. To simulate the NORCCAP trial, we adjusted MISCAN-Colon to the demography and screening behavior of the NORCCAP trial population.

NORCCAP Trial

In the NORCCAP trial, individuals between the ages of 50 and 65 years from 2 Norwegian regions were randomly assigned to either a control group (n = 78,220) or an intervention group that consisted of 2 arms (n = 10,283 and n = 10,289). Since there was no screening program in place in Norway during the study period, the control group did not receive routine CRC screening.³ In the intervention arm, individuals were offered a once-only sigmoidoscopy (arm 1, n = 10,283) or sigmoidoscopy with a qualitative fecal occult blood test (FOBT) (arm 2, n = 10,289).⁴

The trial was carried out in 2 phases; individuals born from 1935 to 1945 were selected and randomized to undergo screening in 1999 and 2000 (i.e., 53–65 years old at time of screening), and individuals born from 1946 to 1950 were selected and randomized to undergo screening in 2001 (i.e., 49–54 years old at the time of screening). Individuals were followed until CRC diagnosis, death, emigration, or 31 December 2015, whichever occurred first.² The lastest paper on long-term effects of the study made no distinction between the 2 different

intervention arms. Therefore, we compared model outcomes with the overall results of the intervention arms and will use the term intervention group when referring to both intervention arms.

Adjustment of MISCAN-Colon to the NORCCAP Trial

We used MISCAN-Colon to simulate a population with an age distribution comparable to the NORCCAP trial (personal communication with research leader G. Hoff, 2016). CRC incidence in the NORCCAP control group was 11% lower than incidence in the whole of Norway. We therefore adjusted the model accordingly by lowering the age-specific onset of adenomas by 11% for all ages. Comparing incidence rates observed in the NORCCAP trial, we assumed that nonadherers had a slightly higher age-specific onset of adenomas for all ages than individuals in the control group (relative risk of 1.05). In addition, age-specific onset in adherers was lowered for all ages to ensure that the overall CRC risk in the intervention group did not differ from the CRC risk in the control group, taking participation rate into account (relative risk of 0.97).

Control group and intervention group were simulated for 16 years according to trial design. For the intervention group, we assumed age-specific participation rates for sigmoidoscopy, FOBT and diagnostic colonoscopy as observed in the NORCCAP trial. Adherence for surveillance colonoscopies was not reported in trial publications and was assumed to be 80%. Test sensitivity of FS and follow-up colonoscopy and specificity of follow-up colonoscopy were based on literature.⁵ Test specificity of FS, FOBT test characteristics and reach of sigmoidoscopy and colonoscopy were based on observations in the NORCCAP study.

Validation Targets

Our primary validation targets were the overall and distal CRC incidence and mortality rate and HRs of overall and distal CRC incidence and mortality at 14- to 16-year follow-up (depending on the year of trial inclusion) in the intervention group relative to the control group. Model outcomes were considered consistent when predicted within 95% confidence intervals (CIs) of the corresponding NORCCAP trial targets.

Validation results

Overall, the MISCAN-Colon predictions for 15-year incidence and mortality reduction from a once-only sigmoidoscopy in the NORCCAP trial were consistent with the trial results. The simulated HR for incidence was 0.84 compared to an observed HR of 0.78 (95% CI: 0.70-0.87) (Supplement 2, table 2), while simulated and observed HR for mortality reduction were 0.72 and 0.79 (95% CI: 0.65-0.96), respectively.

For males, MISCAN-Colon underestimated the impact of screening on CRC incidence compared to the NORCCAP trial results (observed HR: 0.66, 95% CI: 0.57-0.78; simulated HR: 0.81), but MISCAN-Colon predictions of CRC mortality reduction were consistent (observed HR: 0.63, 95% CI: 0.47-0.83; simulated HR: 0.70). For females, MISCAN-Colon predictions for CRC incidence reduction were in line with the trial results (observed HR: 0.92, 95% CI: 0.79-1.07; simulated HR: 0.85), but CRC mortality reduction was overestimated (observed HR: 1.01, 95% CI: 0.77-1.33; simulated HR: 0.76).

Table 1. Hazard ratios: 14-16 years follow-up interventions effects of the NORCCAP trial including 95% confidence intervals for these effects and MISCAN- Colon predictions of these effects.^a NORCCAP trial results were derived from Holme et al. 2018²

						Cases per 10	00,000 person-year	s			
Gender	Outcome	CRC location	Observed HR	Confidence interval	Simulated HR	Observed (control) ^b	Confidence Interval	Simulated (control) ^c	Observed (intervention group)	Confidence Interval	Simulated (intervention group) ^d
Both ^e	Incidence	Overall	0.78	(0.70-0.87)	0.84	174.5	(166.9-182.1)	174.5	135.9	(122.5-149.3)	146.5
Both ^e	Mortality	Overall	0.79	(0.65-0.96)	0.72	52.9	(48.8-57)	51.2	41.9	(34.5-49.3)	36.7
Male	Incidence	Overall	0.66	(0.57-0.78)	0.81	196.9	(185.4-208.4)	195.4	131.4	(112.5-150.3)	158.9
Male	Mortality	Overall	0.63	(0.47-0.83)	0.70	63.3	(57-69.6)	61.6	40.0	(29.6-50.4)	43.0
Female	Incidence	Overall	0.92	(0.79-1.07)	0.85	153.1	(143.2-163)	152.7	140.1	(121.0-159.2)	130.4
Female	Mortality	Overall	1.01	(0.77-1.33)	0.76	43.3	(38.2-48.4)	39.0	43.7	(33.1-54.3)	29.5
Bothe	Incidence	Distal	0.68	(0.58-0.79)	0.80	98.5	(92.8-104.2)	96.2	67.1	(57.7-76.5)	77.3
Both ^e	Mortality	Distal	0.83	(0.64-0.87)	0.65	27.8	(24.8-30.8)	28.5	23.4	(17.8-29.0)	19.0
Male	Incidence	Distal	0.59	(0.48-0.73)	0.80	124.3	(115.1-133.5)	119.7	74.3	(60.1-88.5)	95.4
Male	Mortality	Distal	0.65	(0.45-0.93)	0.66	37.3	(32.4-42.2)	35.6	24.6	(16.5-32.7)	23.5
Female	Incidence	Distal	0.81	(0.64-1.02)	0.81	74.3	(67.4-81.2)	74.8	60.1	(47.6-72.6)	60.8
Female	Mortality	Distal	1.17	(0.79-1.73)	0.69	18.8	(15.4-22.2)	18.0	22.2	(14.6-29.8)	12.4
Bothe	Incidence	Proximal	0.92	(0.78-1.08)	0.88	72.0	(67.2-76.8)	78.3	66.1	(56.7-75.5)	69.2
Bothe	Mortality	Proximal	0.71	(0.52-0.98)	0.78	22.7	(20-25.4)	22.7	16.2	(11.6-20.8)	17.7
Male	Incidence	Proximal	0.81	(0.63-1.04)	0.84	67.6	(60.9-74.3)	76.3	55.1	(42.9-67.3)	63.8
Male	Mortality	Proximal	0.60	(0.37-0.96)	0.75	23.3	(19.5-27.1)	26.2	14.1	(7.9-20.3)	19.7
Female	Incidence	Proximal	1.01	(0.82-1.25)	0.89	76.1	(69.2-83)	77.9	76.5	(62.4-90.6)	69.6
Female	Mortality	Proximal	0.83	(0.54-1.26)	0.81	22.2	(18.6-25.8)	21.0	18.2	(11.4-25.0)	17.1

Shading indicates model predictions outside confidence intervals of the trial. Blu shading indicates underestimation by the model, while orange shading indicates overestimation. Abbreviations: HR, hazard ratio; CRC, colorectal cancer.; NORCCAP trial, Norwegian Colorectal CAncer Prevention trial.

a. NORCCAP is screening trial comparing effectiveness reducing CRC mortality of once-only flexible sigmoidoscopy to no screening. Validation has been performed as described previously.1

b. For observed values, the number of distal and proximal CRC cases and deaths are less than the total number of overall CRC cases and deaths. This is due to some unclassified cancers in the NORCCAP trial. For simulated values, the number of distal and proximal CRC cases are equal to the total number of overall CRC cases and deaths, since there is no correction for unclassified cancers. MISCAN-Colon is therefore more likely to overestimate proximal and distal CRC cases and deaths compared to the NORCCAP trial results.

c. Adenoma onset for all ages was adjusted to match overall CRC incidence in control group

d. Adenoma onset for all ages was adjusted to match the risk difference between CRC incidence in the control group versus non adherers

e. For the results of both genders, aggregated data was used.

References


- 1. Buskermolen M, Gini A, Naber SK, et al. Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. Med Decis Making 2018;38(8):917-29.
- 2. Holme O, Loberg M, Kalager M, et al. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Ann Intern Med 2018.
- 3. Holme O, Loberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014;**312**(6):606-15.
- 4. Gondal G, Grotmol T, Hofstad B, et al. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;**38**(6):635-42.
- 5. Van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. The American journal of gastroenterology 2006;**101**(2):343-50.

Appendix 4: MISCAN-Colon predictions with 15 year follow-up stratified for colorectal cancer risk, age and gender


Note: For consistency and completeness, we present outcomes for all combinations of colorectal cancer risk, age and gender. However, with current discriminatory performance of risk calculators, many of these combinations will be obsolete or very rare. For example according to the Qcancer risk calculator, the 15-year colorectal cancer risk in women aged 50 years varies between 0.9% without risk factors and 2.2% (22 per 1000). with all risk factors. Similarly, 15-year colorectal cancer risk in men aged 75 years varies between 6.4% without any risk factors and 18.6% with all risk factors. Thus results presented for 50-54y old women with a 7% colorectal cancer risk and 75-79y old men with 3% colorectal cancer risk (and many other combinations) are currently not applicable.

Figure 1: MISCAN-Colon predictions of colorectal cancer mortality and incidence reduction per 1000 individuals, using FIT, flexible sigmoidoscopy or colonoscopy. Results are stratified by CRC risk and sex. Individuals were followed-up during 15 years.

a. Colorectal cancer deaths prevented




b. Colorectal cancer cases prevented




Abbreviations: Colo, colonoscopy; CRC, colorectal cancer; FIT, faecal immunochemical test; FS, flexible sigmoidoscopy.

Figure 2: MISCAN-Colon predictions of complications per 1000 individuals, using FIT, flexible sigmoidoscopy or colonoscopy. Results are stratified by CRC risk and age. Individuals were followed-up during 15 years.


a. Number of perforation complications



b. Number of abdominal complications



c. Number of cardiovascular complications



Abbreviations: Colo, colonoscopy; CRC, colorectal cancer; FIT, faecal immunochemical test; FS, flexible sigmoidoscopy.

Tables: MISCAN-Colon predictions stratified for colorectal cancer risk, age and sex.

Note: For consistency and completeness, we present outcomes for all combinations of colorectal cancer risk, age and gender. However, with current discriminatory performance of risk calculators, many of these combinations will be obsolete or very rare. For example according to the Qcancer risk calculator, the 15-year colorectal cancer risk in women aged 50 years varies between 0.9% without risk factors and 2.2% with all risk factors. Similarly, 15-year colorectal cancer risk in men aged 75 years varies between 6.4% without any risk factors and 18.6% with all risk factors. Thus results presented for 50-54y old women with a 7% colorectal cancer risk and 75-79y old men with 3% colorectal cancer risk (and many other combinations) are currently not applicable.

Table 1: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 50-54, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in men aged 52 years varies between 1.2% without risk factors and 4.3% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-5	-1	53	2	1.4	6893	211	39	0.4	0	6 0	.9 0.03
Annual FIT	9	1	63	2	1.6	11882	329	48	0.5	0.	7 1	.1 0.03
Sigmoidoscopy once-only	25	3	47	1	1.2	1000	113	36	0.4	0.	6 0	.9 0.02
Colonoscopy once-only	32	3	58	2	1.5	1000	1000	42	0.5	0.	8 1	.1 0.03

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-7	-1	51	3	2.5	6641	274	80	0.9	1	.2 1	.8 0.05
Annual FIT	7	1	62	4	3	11276	395	98	1.1	1	.5 2	.3 0.06
Sigmoidoscopy once-only	24	5	44	3	2.1	1000	226	68	0.8	1	.1 1	.6 0.05
Colonoscopy once-only	30	6	55	3	2.7	1000	1000	82	1.1	1	.5 2	.2 0.06

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.6% (6 per 1000).

c. 3% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	-7	-2	52	5	3.7	6405	332	121	1.3	1	.8 2	.8 0.08
Annual FIT	7	2	62	6	4.5	10716	456	149	1.6	2	.2 3	.4 0.09
Sigmoidoscopy once-only	23	7	44	4	3.1	1000	328	103	1.2	1	.7 2	.4 0.07
Colonoscopy once-only	30	9	55	5	3.9	1000	1000	124	1.6	2	.2 3	.2 0.09

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 0.9% (9 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-7	-3	52	6	4.8	6160	390	165	1.8	2.	.5 3.	7 0.1
Annual FIT	8	3	63	7	5.8	10133	515	205	2.2		3 4.	6 0.13
Sigmoidoscopy once-only	24	10	46	5	4.2	1000	426	147	1.6	2.	.3 3.	4 0.1
Colonoscopy once-only	31	12	57	7	5.2	1000	1000	174	2.1		3 4.	4 0.13

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.2% (12 per 1000).

e. 5% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	-6	-3	52	8	5.9	5930	443	209	2.2	3	.1 4	.7 0.13
Annual FIT	9	5	64	9	7.3	9608	567	260	2.7	3	.8 5	.7 0.16
Sigmoidoscopy once-only	25	12	47	7	5.3	1000	508	195	2.1		3 4	.4 0.13
Colonoscopy once-only	30	15	57	8	6.5	1000	1000	226	2.7	3	.8 5	.5 0.16

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.5% (15 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-4	-2	53	9	7.1	5727	488	252	2.6	3.	7 5	.6 0.16
Annual FIT	10	6	64	11	8.5	9146	611	312	3.2	4.	5 6	.8 0.19
Sigmoidoscopy once-only	26	16	49	9	6.6	1000	576	245	2.7	3.	8 5	.5 0.16
Colonoscopy once-only	31	19	58	10	7.8	1000	1000	280	3.3	4.	6 6	.7 0.19

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 1.8% (18 per 1000).

g. 7% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-2	-2	55	11	8.4	5525	530	294	3.1	4.	.3 6	.6 0.18
Annual FIT	12	8	65	13	9.9	8693	652	365	3.7	5.	.3	8 0.22
Sigmoidoscopy once-only	27	19	52	11	8	1000	636	298	3.3	4.	.6 6	.8 0.19
Colonoscopy once-only	32	22	60	12	9.2	1000	1000	336	3.9	5.	.5	8 0.23

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.0% (20 per 1000).

Table 2: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 55-59, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in men aged 57 years varies between 2.0% without risk factors and 6.1% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	5	1	56	2	0.9	6757	192	30	0.4	0	.6	1 0.03
Annual FIT	17	2	66	2	1.1	11703	307	36	0.5	0	.7 1	2 0.03
Sigmoidoscopy once-only	31	3	58	2	0.9	1000	86	31	0.5	0	.7	1 0.03
Colonoscopy once-only	35	3	65	2	1.1	1000	1000	35	0.6	0	.8 1	2 0.03

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	0	0	52	3	1.7	6561	239	62	0.9	1.	2	2 0.05
Annual FIT	13	3	63	4	2	11236	356	76	1.1	1.	5 2	2.4 0.06
Sigmoidoscopy once-only	29	6	52	3	1.6	1000	174	63	0.9	1.	3	2 0.06

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	complications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	All-cause mortality Scree reduction (%)	Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Colonoscopy once-only	35	7	62	4	2	1000	1000	72	1.2	1	6	2.5 0.07

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.6% (6 per 1000).

c. 3% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	complications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-1	0	51	5	2.4	6360	287	95	1.3	1	.9	3 0.08
Annual FIT	12	4	61	6	2.9	10764	405	116	1.6	2	.3 3	.7 0.1
Sigmoidoscopy once-only	28	8	50	5	2.3	1000	262	94	1.4	1	.9	3 0.08
Colonoscopy once-only	34	10	60	6	2.8	1000	1000	109	1.8	2	.5 3	0.1

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 0.9% (9 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	-1	-1	52	6	3.1	6163	333	128	1.8	2	.5	4 0.11
Annual FIT	12	5	62	7	3.7	10305	453	158	2.2	3	.1 4	.9 0.13
Sigmoidoscopy once-only	27	11	49	6	2.9	1000	346	127	1.9	2	.6	4 0.11
Colonoscopy once-only	34	13	59	7	3.5	1000	1000	148	2.3	3	.3	5 0.14

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.2% (12 per 1000).

e. 5% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-2	-1	52	8	3.9	5973	377	161	2.3	3	.2	5 0.13
Annual FIT	12	6	62	10	4.7	9858	498	198	2.8	3	.9 6	0.16
Sigmoidoscopy once-only	28	14	51	8	3.8	1000	421	163	2.3	3	.3 5	0.14
Colonoscopy once-only	34	17	61	9	4.6	1000	1000	188	2.9	4	.1 6	i.3 0.17

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.5% (15 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-1	-1	53	10	4.7	5781	421	197	2.8	3.	.8 6	.1 0.16
Annual FIT	12	7	63	12	5.6	9418	542	243	3.3	4.	.7 7	.4 0.2
Sigmoidoscopy once-only	28	17	51	9	4.6	1000	494	204	2.9	4.	.1 6	.3 0.17
Colonoscopy once-only	34	20	61	11	5.4	1000	1000	233	3.6		5 7	.7 0.21

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 1.8% (18 per 1000).

g. 7% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-1	0	53	11	5.4	5601	461	231	3.2	4	.5 7	.2 0.19
Annual FIT	13	9	63	14	6.5	9008	581	285	3.9	5	.4 8	.7 0.23
Sigmoidoscopy once-only	29	20	53	11	5.4	1000	556	246	3.5	4	.9 7	.5 0.21
Colonoscopy once-only	34	24	62	13	6.3	1000	1000	278	4.2	5	.9	9 0.25

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.2% (22 per 1000).

Table 3: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 60-64, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in men aged 62 years varies between 3.0% without risk factors and 8.6% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	11	1	60	2	0.6	6500	177	23	0.5	0	.6 1	.1 0.03
Annual FIT	21	2	67	2	0.7	11303	287	28	0.5	0	.7 1	.2 0.03
Sigmoidoscopy once-only	33	3	62	2	0.6	1000	72	27	0.5	0	.7 1	.2 0.03
Colonoscopy once-only	38	4	69	2	0.7	1000	1000	29	0.6	0	.8 1	.4 0.04

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	mplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	6	1	56	4	1.1	6341	213	49	0.9	1.3	3 2.2	0.06
Annual FIT	18	4	65	4	1.3	10934	325	60	1.1	1.5	5 2.6	0.07
Sigmoidoscopy once-only	32	6	59	4	1.2	1000	140	55	1.1	1.5	5 2.4	0.06

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	complications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	All-cause mortality Screening tests reduction (%)	Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Colonoscopy once-only	37	7	68	4	1.4	1000	1000	62	1.3	1	8 2	2.8 0.07

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.6% (6 per 1000).

c. 3% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	5	1	53	5	1.6	6170	254	77	1.4		2 3	.3 0.08
Annual FIT	17	5	63	6	1.9	10531	367	94	1.7	2	.4	4 0.1
Sigmoidoscopy once-only	31	9	55	5	1.6	1000	215	85	1.6	2	.2 3	.6 0.09
Colonoscopy once-only	37	11	65	6	1.9	1000	1000	96	2	2	.7 4	.4 0.12

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 1.0% (10 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	4	1	52	7	2	6000	293	104	1.9	2	.7 4	.5 0.11
Annual FIT	16	6	63	8	2.4	10137	407	128	2.3	3	.2 5	.4 0.14
Sigmoidoscopy once-only	31	12	56	7	2.1	1000	289	114	2.1		3 4	.8 0.13
Colonoscopy once-only	37	15	65	8	2.5	1000	1000	131	2.6	3	.7 5	.9 0.16

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.3% (13 per 1000).

e. 5% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	3	1	53	8	2.5	5838	331	132	2.4	3	.3 5.	6 0.14
Annual FIT	16	8	63	10	3	9757	446	162	2.9	4	.1 6.	8 0.17
Sigmoidoscopy once-only	30	15	55	9	2.6	1000	359	145	2.7	3	.7	6 0.16
Colonoscopy once-only	36	18	65	10	3.1	1000	1000	165	3.3	4	.6 7.	4 0.2

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.6% (16 per 1000). (16 per 1000).

f. 6% colorectal cancer risk

Screening strategy	Colorectal cancer incidence reduction (%)	Number of prevented colorectal cancer cases	Colorectal cancer mortality reduction (%)	Number of prevented colorectal cancer deaths	All-cause mortality reduction (%)	Screening tests	Individuals with at least one colonoscopy	Individuals with at least two colonoscopies	Risk of complications			
									Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	3	2	52	10	3	5676	367	159	2.9		4 6	.8 0.17
Annual FIT	16	9	63	12	3.6	9389	484	196	3.5	4	.9 8	.2 0.21
Sigmoidoscopy once-only	31	18	56	11	3.1	1000	425	177	3.3	4	.5 7	.3 0.19
Colonoscopy once-only	36	22	64	12	3.6	1000	1000	202	4	5	.5 8	.9 0.23

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 1.9% (19 per 1000). (19 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	4	3	52	12	3.5	5517	404	187	3.4	4	.7 7.	9 0.2
Annual FIT	16	12	63	14	4.2	9018	520	231	4.1	5	.7 9.	6 0.24
Sigmoidoscopy once-only	31	22	55	12	3.6	1000	485	212	3.9	5	.4 8.	7 0.23
Colonoscopy once-only	37	26	64	15	4.3	1000	1000	239	4.7	6	.5 10.	5 0.27

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.3% (23 per 1000).

Table 4: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 65-69, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in men aged 67 years varies between 4.2% without risk factors and 11.8% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	13	1	58	2	0.3	5488	149	19	0.5	0.	6 1	.1 0.03
Annual FIT	22	2	66	2	0.4	9751	247	23	0.6	0.	8 1	.3 0.03
Sigmoidoscopy once-only	33	3	65	2	0.4	1000	66	24	0.6	0.	8 1	.4 0.04
Colonoscopy once-only	37	4	70	2	0.4	1000	1000	26	0.7	0.	9 1	.6 0.04

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	mplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	12	2	54	4	0.7	5377	180	42	1	1.3	3 2.3	0.06
Annual FIT	21	4	63	4	0.8	9479	280	51	1.2	1.6	5 2.8	3 0.07
Sigmoidoscopy once-only	34	7	61	4	0.7	1000	127	51	1.2	1.7	2.9	0.07

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of	complications		
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascu ever		procedure ed mortality
Colonoscopy once-only	38	8	68	5	0.8	1000	1000	57	1.5		2	3.4	0.09

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.7% (7 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	10	3	52	5	0.9	5260	212	66	1.5		2 3	.5 0.09
Annual FIT	20	6	61	6	1.1	9191	315	80	1.8	2	.5 4	.3 0.11
Sigmoidoscopy once-only	33	10	59	6	1	1000	194	79	1.9	2	.6 4	.4 0.11
Colonoscopy once-only	38	11	66	7	1.1	1000	1000	89	2.3	3	.1 5	.3 0.13

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 1.0% (10 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	9	3	52	7	1.2	5140	246	90	2	2	.7 4	.8 0.12
Annual FIT	19	7	61	8	1.4	8893	352	110	2.5	3	.4 5	.9 0.15
Sigmoidoscopy once-only	32	13	58	8	1.3	1000	262	108	2.5	3	.5 5	.9 0.15
Colonoscopy once-only	37	15	66	9	1.5	1000	1000	121	3.1	4	2 7	0.18

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.3% (13 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	8	4	51	8	1.5	5024	278	114	2.5	3.	.5	6 0.15
Annual FIT	18	9	60	10	1.7	8607	386	139	3.1	4.	.3 7	0.18
Sigmoidoscopy once-only	32	16	57	9	1.6	1000	328	138	3.2	4.	.4 7	.5 0.19
Colonoscopy once-only	38	19	65	11	1.8	1000	1000	155	3.9	5.	.3	9 0.23

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.7% (17 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	8	5	51	10	1.7	4910	310	137	3	4.	.1 7.	3 0.18
Annual FIT	18	11	60	12	2	8326	420	168	3.7	5.	.1 8.	9 0.22
Sigmoidoscopy once-only	32	19	57	11	1.9	1000	390	167	3.8	5.	3	9 0.23
Colonoscopy once-only	37	22	65	13	2.2	1000	1000	188	4.6	6.	.4 10.	.8 0.27

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 2.0% (20 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	8	6	51	12	2	4797	341	162	3.6	4.	.9 8.	5 0.21
Annual FIT	19	13	60	14	2.4	8051	453	199	4.4		6 10.	5 0.26
Sigmoidoscopy once-only	33	23	57	13	2.2	1000	450	199	4.5	6.	.3 10.	6 0.27
Colonoscopy once-only	37	26	65	15	2.5	1000	1000	223	5.5	7.	.5 12.	7 0.32

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.3% (23 per 1000).

Table 5: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 70-74, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in men aged 72 years varies between 5.6% without risk factors and 16.1% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	12	1	56	2	0.2	3617	104	16	0.4	0.	5	1 0.02
Annual FIT	18	2	62	2	0.2	6509	173	20	0.5	0.	7 1	2 0.03
Sigmoidoscopy once-only	29	3	64	2	0.2	1000	69	24	0.6	0.	9 1	5 0.04
Colonoscopy once-only	33	3	69	2	0.2	1000	1000	26	0.7		1 1	8 0.04

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	10	2	53	4	0.3	3564	130	35	0.8	1.	1	2 0.05
Annual FIT	17	3	61	4	0.4	6362	204	44	1	1.	4 2	.5 0.06
Sigmoidoscopy once-only	29	6	62	4	0.4	1000	132	52	1.3	1.	8 3	.2 0.08

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	complications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	All-cause mortality Screening tests reduction (%)	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality	
Colonoscopy once-only	34	7	69	5	0.4	1000	1000	57	1.6	2	1.2 3	3.9 0.1

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.7% (7 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	complications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	10	3	51	5	0.5	3509	158	54	1.2	1	7	3 0.07
Annual FIT	17	5	59	6	0.6	6208	236	68	1.6	2	2 3	.9 0.09
Sigmoidoscopy once-only	30	9	60	6	0.6	1000	199	80	2.1	2	8	5 0.12
Colonoscopy once-only	35	10	68	7	0.7	1000	1000	89	2.5	3	5 €	i.1 0.15

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 1.1% (11 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	9	4	50	7	0.6	3452	186	74	1.7	2	.3 4	.1 0.1
Annual FIT	16	6	59	8	0.7	6049	270	94	2.2	2	.9 5	0.13
Sigmoidoscopy once-only	30	12	60	8	0.8	1000	268	110	2.8	3	.9 6	i.8 0.17
Colonoscopy once-only	34	14	67	9	0.8	1000	1000	123	3.5	4	.8 8	0.21

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.4% (14 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	9	4	50	9	0.8	3398	214	93	2.1	2	.9 5	.1 0.12
Annual FIT	16	8	59	10	0.9	5898	302	119	2.7	3	.7 6	.6 0.16
Sigmoidoscopy once-only	30	15	60	10	0.9	1000	333	140	3.6	4	.9 8	.6 0.21
Colonoscopy once-only	34	17	67	12	1.1	1000	1000	157	4.4		6 10	.5 0.26

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.7% (17 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	9	5	49	10	0.9	3345	241	113	2.5	3	.4 6	.1 0.15
Annual FIT	16	10	59	12	1.1	5748	334	144	3.3	4	.5	8 0.19
Sigmoidoscopy once-only	31	18	60	12	1.1	1000	397	171	4.3	5	.9 10	.4 0.26
Colonoscopy once-only	35	21	67	14	1.2	1000	1000	191	5.3	7	.2 12	.7 0.31

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 2.1% (21 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	-
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	9	6	49	12	1.1	3291	267	132	2.9		4 7	.2 0.17
Annual FIT	16	11	59	14	1.3	5599	365	169	3.8	5	.2 9	.3 0.23
Sigmoidoscopy once-only	31	21	60	14	1.3	1000	457	203	5.1	6	.9 12	.2 0.3
Colonoscopy once-only	35	24	67	16	1.5	1000	1000	226	6.1	8	.4 14	.8 0.36

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.4% (24 per 1000).

Table 6: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for men, aged 75-79, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in men aged 77 years varies between 6.7% without risk factors and 21.4% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	3	0	43	2	0.1	1723	58	12	0.3	0	.4 0	.7 0.02
Annual FIT	6	1	51	2	0.1	2792	86	16	0.4	0	.5	1 0.02
Sigmoidoscopy once-only	21	2	65	2	0.1	1000	81	27	0.8	1	.1	2 0.05
Colonoscopy once-only	23	2	69	3	0.1	1000	1000	30	1	1	.3 2	.5 0.06

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.4% (4 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	mplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	1	0	40	3	0.1	1712	78	25	0.6	3.0	3 1.5	0.04
Annual FIT	4	1	48	4	0.2	2754	112	32	0.8	1.3	L 2	2 0.05
Sigmoidoscopy once-only	19	4	61	5	0.2	1000	155	57	1.7	2.3	3 4.2	2 0.1

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	complications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Colonoscopy once-only	23	5	68	5	0.2	1000	1000	63	2.1	2	2.9 5	5.3 0.13

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.7% (7 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	1	0	39	4	0.2	1699	100	38	0.9	1	.2 2	.3 0.05
Annual FIT	4	1	47	5	0.2	2713	140	50	1.2	1	.7 3	.1 0.07
Sigmoidoscopy once-only	20	6	61	7	0.3	1000	234	90	2.7	3	.6 6	.7 0.16
Colonoscopy once-only	23	7	68	7	0.3	1000	1000	100	3.4	4	.6 8	.4 0.2

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 1.1% (11 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	1	0	40	6	0.3	1687	120	50	1.2	1	.6	3 0.07
Annual FIT	4	2	48	7	0.3	2674	165	66	1.6	2	.2	4 0.1
Sigmoidoscopy once-only	21	8	62	9	0.4	1000	305	120	3.6	4	.8 8.	3.9 0.21
Colonoscopy once-only	24	10	69	10	0.5	1000	1000	133	4.5	6	.1 11	1 0.27

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.5% (15 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	0	0	38	7	0.3	1676	141	64	1.5	2.	1 3.	8 0.09
Annual FIT	3	2	47	9	0.4	2635	192	85	2	2.	8 5.	1 0.12
Sigmoidoscopy once-only	21	10	61	11	0.5	1000	381	154	4.5	6.	2 11.	.3 0.27
Colonoscopy once-only	24	12	68	12	0.6	1000	1000	171	5.7	7.	7 14.	1 0.34

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.8% (18 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	1	1	38	8	0.4	1664	162	77	1.8	2	.5 4.	5 0.11
Annual FIT	4	2	47	10	0.5	2596	217	102	2.5	3	.3 6.	1 0.15
Sigmoidoscopy once-only	21	13	61	13	0.6	1000	450	188	5.5	7	.4 13.	.5 0.32
Colonoscopy once-only	24	14	68	15	0.7	1000	1000	208	6.7	9	.2 16.	7 0.4

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 2.2% (22 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests reduction (%) 0.4 1652		with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	1	1	39	10	0.4	1652	182	90	2.1	2	.9 5	.3 0.13
Annual FIT	4	3	47	12	0.5	2557	244	120	2.9	3	.9 7	.1 0.17
Sigmoidoscopy once-only	21	15	62	16	0.7	1000	516	223	6.4	8	.6 15	.8 0.38
Colonoscopy once-only	24	17	69	18	0.8	1000	1000	246	7.8	10	.5 19	.3 0.46

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.6% (26 per 1000).

Table 7: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 50-54, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in women aged 52 years varies between 1.0% without risk factors and 2.6% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests		with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	0	0	50	1	1.8	6929	224	44	0.5	0.	6	1 0.03
Annual FIT	12	1	60	2	2.2	11898	345	52	0.6	0.	8 1	1.2 0.03
Sigmoidoscopy once-only	24	2	42	1	1.5	1000	113	35	0.4	0.	5 0	0.02
Colonoscopy once-only	33	3	55	2	2	1000	1000	46	0.6	0.	8 1	1.1 0.03

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-3	-1	50	3	3.4	6613	299	89	0.9	1.	3	2 0.06
Annual FIT	11	2	60	3	4.1	11143	422	108	1.1	1.	6 2	.4 0.07
Sigmoidoscopy once-only	21	4	39	2	2.7	1000	221	67	0.7		1 1	5 0.04

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	complications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening test	Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Colonoscopy once-only	32	6	56	3	3.8	1000	1000	91	1.1	1	6	2.3 0.07

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.5% (5 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tes reduction (%)		with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	-3	-1	50	4	5	6311	368	136	1.4		2	3 0.08
Annual FIT	10	3	59	5	5.9	10431	493	164	1.7	2	.4 3	.6 0.1
Sigmoidoscopy once-only	21	6	40	3	4	1000	319	104	1.1	1	.6 2	.3 0.07
Colonoscopy once-only	31	9	55	4	5.5	1000	1000	140	1.7	2	.4 3	.4 0.1

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 0.8% (8 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests al reduction (%)	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality	
Biennial FIT	-2	-1	51	5	6.6	6017	434	185	1.9	2	.7 4	.1 0.11
Annual FIT	11	4	61	6	7.8	9751	558	224	2.3	3	.2 4	8 0.13
Sigmoidoscopy once-only	23	9	42	4	5.3	1000	410	149	1.6	2	.2 3	0.09
Colonoscopy once-only	31	13	57	6	7.3	1000	1000	196	2.3	3	.2 4	.7 0.13

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.1% (11 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests reduction (%)		with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	0	0	51	7	8	5756	490	233	2.4	3.	4 5	.1 0.14
Annual FIT	12	6	60	8	9.5	9159	612	282	2.8		4	6 0.17
Sigmoidoscopy once-only	24	12	43	6	6.8	1000	487	197	2.1	2.	9 4	.3 0.12
Colonoscopy once-only	32	16	58	8	9.1	1000	1000	253	2.9	4.	1 5	.9 0.17

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.3% (13 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests al reduction (%) s	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality	
Biennial FIT	1	1	53	8	9.5	5507	540	280	2.9		4 6	.1 0.17
Annual FIT	14	9	62	10	11.2	8604	660	340	3.4	4	.8 7	.2 0.2
Sigmoidoscopy once-only	25	15	46	7	8.4	1000	554	251	2.6	3	.7 5	.5 0.16
Colonoscopy once-only	32	19	59	9	10.7	1000	1000	313	3.5	4	.9 7	.2 0.21

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 1.6% (16 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests reduction (%)		with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	3	2	54	10	11.1	5271	586	326	3.3	4.	.7 7.	1 0.2
Annual FIT	16	11	63	12	13	8094	703	396	4	5.	.6 8.	4 0.23
Sigmoidoscopy once-only	27	19	50	9	10.2	1000	612	307	3.2	4.	.6 6.	7 0.19
Colonoscopy once-only	33	23	61	11	12.4	1000	1000	374	4.1	5.	.8 8.	5 0.24

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 1.9% (19 per 1000).

Table 8: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 55-59, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in women aged 57 years varies between 1.6% without risk factors and 3.6% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests reduction (%)		with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	6	1	56	2	1.4	6884	205	35	0.5	0	.7 1	.1 0.03
Annual FIT	19	2	66	2	1.6	11878	323	41	0.6	0	.8 1	.3 0.03
Sigmoidoscopy once-only	28	3	52	1	1.2	1000	89	31	0.4	0	.6	1 0.03
Colonoscopy once-only	36	4	65	2	1.6	1000	1000	39	0.6	0	.8 1	.3 0.04

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

•	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	mplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	3	1	51	3	2.4	6626	264	72	1	1.4	2.2	0.06
Annual FIT	15	3	61	3	2.8	11271	383	86	1.2	1.6	2.6	0.07
Sigmoidoscopy once-only	25	5	46	3	2.1	1000	174	60	0.9	1.2	1.8	3 0.05

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	complications		
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests reduction (%)	Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events		
Colonoscopy once-only	34	7	60	3	2.8	1000	1000	79	1.2	1	7	2.6	0.07

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.5% (5 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	1	0	52	4	3.5	6373	321	110	1.5	2	.1 3	.3 0.09
Annual FIT	15	4	61	5	4.1	10670	442	132	1.8	2	.5 3	.9 0.11
Sigmoidoscopy once-only	25	7	44	4	3	1000	259	91	1.3	1	.8 2	.7 0.07
Colonoscopy once-only	34	10	60	5	4	1000	1000	120	1.8	2	.6 3	.9 0.11

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 0.8% (8 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	2	1	51	6	4.6	6132	375	147	2	2	.7 4	.4 0.12
Annual FIT	15	6	61	7	5.4	10112	496	176	2.4	3	.3 5	.2 0.14
Sigmoidoscopy once-only	25	10	44	5	3.9	1000	335	124	1.7	2	.4 3	.6 0.1
Colonoscopy once-only	34	14	59	7	5.3	1000	1000	161	2.4	3	.4 5	.2 0.14

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.1% (11 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	2	1	52	7	5.7	5893	427	185	2.5	3.	.5 5.	5 0.15
Annual FIT	15	7	61	8	6.7	9565	547	223	3	4.	.1 6.	6 0.17
Sigmoidoscopy once-only	25	13	45	6	5	1000	407	161	2.2	3.	.1 4.	7 0.13
Colonoscopy once-only	34	17	60	8	6.5	1000	1000	208	3.1	4.	.3 6.	6 0.18

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.4% (14 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	3	2	52	9	6.8	5670	473	223	3	4.	2 6.	.6 0.18
Annual FIT	16	10	62	10	8	9063	593	269	3.5	4.	9 7.	.8 0.21
Sigmoidoscopy once-only	26	16	47	8	6.0	1000	472	200	2.7	3.	8 5.	.8 0.16
Colonoscopy once-only	35	21	61	10	7.9	1000	1000	255	3.7	5.	2 7.	.9 0.22

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 1.7% (17 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	4	3	53	10	7.8	5462	515	261	3.5	4.	9 7	.7 0.21
Annual FIT	17	12	62	12	9.1	8600	633	315	4.1	5.	.7 9	.1 0.24
Sigmoidoscopy once-only	27	19	49	9	7.2	1000	529	243	3.3	4.	6	7 0.19
Colonoscopy once-only	35	24	62	12	9	1000	1000	303	4.3		6 9	.3 0.25

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 1.9% (19 per 1000).

Table 9: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 60-64, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in women aged 62 years varies between 2.2% without risk factors and 4.8% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	11	1	57	2	0.9	6760	28	62	0.5	0.	7 1.	.2 0.03
Annual FIT	21	2	66	2	1	11710	33	77	0.6	0.	8 1.	.4 0.04
Sigmoidoscopy once-only	31	3	56	2	0.9	1000	28	81	0.5	0.	7 1.	.2 0.03
Colonoscopy once-only	38	4	68	2	1	1000	33	98	0.7	0.	9 1.	.5 0.04

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

•	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	8	2	54	3	1.6	6551	238	59	1.1	1.	5 2.5	0.06
Annual FIT	20	4	63	4	1.9	11220	354	70	1.3	1.	7 2.9	0.07
Sigmoidoscopy once-only	30	6	51	3	1.5	1000	143	55	1	1.	4 2.2	2 0.06

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	complications		
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events			
Colonoscopy once-only	37	7	64	4	1.9	1000	1000	69	1.3	1	9	3	0.08

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.6% (6 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	6	2	52	4	2.3	6335	286	90	1.6	2.	.2 3.	7 0.09
Annual FIT	18	5	62	5	2.7	10713	403	108	1.9	2.	.6 4.	4 0.11
Sigmoidoscopy once-only	28	8	49	4	2.1	1000	215	83	1.5		2 3.	.3 0.09
Colonoscopy once-only	37	11	64	5	2.7	1000	1000	106	2	2.	.9 4.	6 0.12

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 0.8% (8 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	5	2	52	6	3	6123	332	122	2.1		3	5 0.13
Annual FIT	18	7	62	7	3.6	10230	449	146	2.6	3	.5 5	.9 0.15
Sigmoidoscopy once-only	28	11	48	6	2.8	1000	283	111	2	2	.7 4	.4 0.12
Colonoscopy once-only	37	15	64	7	3.7	1000	1000	143	2.7	3	.8 6	.1 0.16

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.2% (12 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	5	3	52	7	3.7	5918	377	153	2.7	3.	7 6.	3 0.16
Annual FIT	18	9	62	9	4.4	9750	495	184	3.2	4.	4 7.	4 0.19
Sigmoidoscopy once-only	27	14	48	7	3.4	1000	349	142	2.5	3.	4 5.	6 0.15
Colonoscopy once-only	37	18	63	9	4.4	1000	1000	182	3.4	4.	8 7.	7 0.2

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.4% (14 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	7	4	52	9	4.4	5722	419	184	3.2	4	4 7	.5 0.19
Annual FIT	19	11	62	11	5.2	9307	537	221	3.8	5	3 8	.8 0.23
Sigmoidoscopy once-only	28	17	49	9	4.1	1000	407	174	3	4	2 6	.7 0.18
Colonoscopy once-only	37	22	63	11	5.3	1000	1000	220	4.1	5	7 9	.2 0.24

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 1.7% (17 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals		Risk of complications					
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality		
Biennial FIT	7	5	52	11	5.1	5528	459	216	3.8	5	.2 8.	7 0.22		
Annual FIT	19	13	62	12	6.0	8866	577	260	4.5	6	.2 10.	3 0.26		
Sigmoidoscopy once-only	29	20	50	10	4.9	1000	464	209	3.6		5 8.	1 0.21		
Colonoscopy once-only	37	26	64	13	6.2	1000	1000	260	4.8	6	.7 10.	7 0.28		

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.0% (20 per 1000).

Table 10: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 65-69, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in women aged 67 years varies between 3.0% without risk factors and 6.2% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	•••	Risk of complications					
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests reduction (%)	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality			
Biennial FIT	17	2	56	2	0.5	5769	161	23	0.5	0	.7 1	3 0.03		
Annual FIT	26	3	62	2	0.6	10241	264	27	0.6	0	.8 1	5 0.04		
Sigmoidoscopy once-only	33	3	58	2	0.5	1000	66	24	0.6	0	.8 1	3 0.03		
Colonoscopy once-only	39	4	66	2	0.6	1000	1000	29	0.7		1 1	7 0.04		

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals	Risk of complications				
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality	
Biennial FIT	14	3	52	3	0.9	5628	198	49	1.1	1.5	5 2.6	0.06	
Annual FIT	23	5	60	4	1.1	9895	304	58	1.3	1.8	3 3.1	0.08	
Sigmoidoscopy once-only	31	6	53	3	1	1000	125	50	1.1	1.6	5 2.7	7 0.07	

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals	Risk of complications				
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths	mortality Screening tests reduction (%)	with at least with at least one two colonoscopy colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen proced related morta			
Colonoscopy once-only	38	8	64	4	1.2	1000	1000	62	1.5	2	2.1	3.5 0	

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.6% (6 per 1000).

	Colorectal	Number of		Number of	All-cause		Individuals						
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality	
Biennial FIT	13	4	51	5	1.3	5480	238	77	1.6	2.	2 3.9	9 0.1	
Annual FIT	22	7	59	5	1.6	9527	347	91	2	2.	7 4.7	7 0.12	
Sigmoidoscopy once-only	30	9	51	5	1.4	1000	189	77	1.7	2.	4 4	4 0.1	
Colonoscopy once-only	39	12	63	6	1.7	1000	1000	96	2.3	3.	2 5.4	4 0.14	

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 0.9% (9 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals		Risk of complications					
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality		
Biennial FIT	12	5	51	6	1.8	5332	278	104	2.2		3 5	.3 0.13		
Annual FIT	22	9	60	7	2.1	9159	389	125	2.7	3	.6 6	.3 0.16		
Sigmoidoscopy once-only	30	12	50	6	1.8	1000	253	104	2.3	3	.1 5	.3 0.13		
Colonoscopy once-only	39	15	64	8	2.2	1000	1000	131	3.1	4	.3 7	.3 0.18		

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.2% (12 per 1000).

	Colorectal	Number of	Colorectal		All-cause		Individuals		Risk of complications				
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality	
Biennial FIT	11	6	51	8	2.2	5186	317	132	2.8	3.	8 6.	.6 0.16	
Annual FIT	22	11	59	9	2.6	8800	429	158	3.3	4.	6	8 0.2	
Sigmoidoscopy once-only	30	15	50	8	2.2	1000	315	132	2.9		4 6.	.7 0.17	
Colonoscopy once-only	39	19	64	10	2.8	1000	1000	166	3.9	5.	4 9.	.2 0.23	

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.5% (15 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals		Risk of complications					
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality		
Biennial FIT	12	7	50	9	2.6	5043	353	159	3.3	4	.6	8 0.2		
Annual FIT	22	13	58	11	3	8452	468	191	4	5	.5 9	.6 0.24		
Sigmoidoscopy once-only	31	18	50	9	2.6	1000	372	161	3.5	4	.8 8	.2 0.21		
Colonoscopy once-only	39	23	63	11	3.3	1000	1000	202	4.7	6	.5 1	11 0.28		

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 1.8% (18 per 1000).

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals						
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality	
Biennial FIT	12	8	50	11	3	4905	389	186	3.9	5	.3 9.	4 0.23	
Annual FIT	22	16	59	13	3.6	8112	506	224	4.7	6	.5 11.	3 0.28	
Sigmoidoscopy once-only	30	21	50	11	3	1000	426	192	4.1	5	.7 9.	.6 0.24	
Colonoscopy once-only	39	27	63	13	3.8	1000	1000	238	5.5	7	.6 12.	8 0.33	

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.1% (21 per 1000)

Table 11: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 70-74, stratified by risk

Note: According to the Qcancer risk calculator, the 15-year colorectal cancer risk in women aged 72 years varies between 3.8% without risk factors and 7.7% with all risk factors.

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	0.18	2	0.53	2	0.997	3754	111	19	0.4	0.	6 1.	.1 0.03
Annual FIT	0.24	2	0.61	2	0.997	6771	183	23	0.5	0.	7 1.	.3 0.03
Sigmoidoscopy once-only	0.33	3	0.58	2	0.997	1000	67	24	0.6	0.	8 1.	.4 0.04
Colonoscopy once-only	0.38	4	0.67	2	0.997	1000	1000	29	0.8	1.	1 1.	.9 0.05

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.3% (3 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of co	mplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	16	3	52	3	0.5	3691	141	39	0.9	1.2	2 2.1	0.05
Annual FIT	22	4	60	4	0.6	6596	218	49	1.1	1.5	5 2.7	0.07
Sigmoidoscopy once-only	31	6	56	4	0.6	1000	124	50	1.2	1.7	7 2.9	0.07

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of o	complications		
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		mortality Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	'	procedure mortality
Colonoscopy once-only	38	8	67	4	0.7	1000	1000	61	1.7	2	.3	4	0.1

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.7% (7 per 1000).

c. 3% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	15	4	51	5	0.81	3626	173	61	1.3	1	.8 3	0.08
Annual FIT	22	7	59	6	0.9	6409	257	76	1.7	2	.3 4	.2 0.1
Sigmoidoscopy once-only	31	9	54	5	0.8	1000	187	77	1.9	2	.6 4	5 0.11
Colonoscopy once-only	39	12	67	7	1	1000	1000	96	2.6	3	.6 6	i.2 0.15

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 1.0% (10 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	14	6	50	7	1	3561	205	160	1.8	2	.4 4	.4 0.11
Annual FIT	21	8	59	8	1.2	6225	295	204	2.3	3	.2 5	.6 0.14
Sigmoidoscopy once-only	30	12	53	7	1.1	1000	249	231	2.5	3	.5 6	.1 0.15
Colonoscopy once-only	38	15	66	9	1.3	1000	1000	287	3.5	4	.8 8	.4 0.21

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.3% (13 per 1000).

e. 5% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	14	7	49	8	1.2	3496	236	82	2.3	3.	.1 5	.5 0.13
Annual FIT	21	10	58	10	1.4	6043	332	103	2.9		4 7	.1 0.17
Sigmoidoscopy once-only	30	15	53	9	1.3	1000	310	104	3.2	4.	.4 7	.7 0.19
Colonoscopy once-only	38	19	66	11	1.6	1000	1000	129	4.4		6 10	.6 0.26

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.7% (17 per 1000).

f. 6% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	14	8	49	10	1.5	3432	267	103	2.7	3	.7 6	.6 0.16
Annual FIT	21	13	59	12	1.7	5865	367	130	3.5	4	.7 8	.5 0.21
Sigmoidoscopy once-only	30	18	53	11	1.6	1000	366	132	3.8	5	.3 9	.2 0.23
Colonoscopy once-only	38	23	66	13	1.9	1000	1000	164	5.3	7	.2 12	.6 0.31

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 2.0% (20 per 1000).

g. 7% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	14	10	49	11	1.7	3370	297	124	3.2	4.	.3 7.	7 0.19
Annual FIT	22	15	58	14	2	5690	402	157	4.1	5.	.5 9.	9 0.24
Sigmoidoscopy once-only	31	22	54	13	1.9	1000	419	161	4.5	6.	.2 10.	8 0.27
Colonoscopy once-only	39	27	66	15	2.3	1000	1000	199	6.1	8.	.3 14.	6 0.36

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.3% (23 per 1000).

Table 12: MISCAN-Colon predictions of benefits and harms of various screening strategies during a follow-up period of 15 years for women, aged 75-79, stratified by risk

a. 1% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	10	1	42	2	0.1	1741	60	10	0.3	0	.4 0	.8 0.02
Annual FIT	14	1	49	2	0.1	2825	89	13	0.4	0	.5	1 0.02
Sigmoidoscopy once-only	27	3	58	2	0.2	1000	74	22	0.7		1 1	.8 0.04
Colonoscopy once-only	33	3	69	3	0.2	1000	1000	26	1	1	.3 2	.4 0.06

Without screening these individuals would have a 1% colorectal cancer risk (10 cases per 1000) and a risk of dying of colorectal cancer of 0.4% (4 per 1000).

b. 2% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	8	2	40	3	0.2	1728	81	21	0.6	0.	.8 1	.5 0.04
Annual FIT	12	2	48	4	0.3	2782	117	27	0.8	1.	.1 2	.1 0.05
Sigmoidoscopy once-only	26	5	57	4	0.3	1000	139	45	1.5	2.	.1 3	.8 0.09
Colonoscopy once-only	32	6	68	5	0.4	1000	1000	55	2.1	2.	.9 5	.3 0.13

Without screening these individuals would have a 1% colorectal cancer risk (20 cases per 1000) and a risk of dying of colorectal cancer of 0.7% (7 per 1000).

c. 3% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	8	2	39	4	0.3	1715	104	31	0.9	1	.3 2	3 0.06
Annual FIT	11	3	48	5	0.4	2738	146	42	1.3	1	.7 3	.1 0.07
Sigmoidoscopy once-only	26	8	56	6	0.4	1000	209	69	2.3	3	.2 5	0.14
Colonoscopy once-only	33	10	69	7	0.5	1000	1000	85	3.3	4	.5 8	3.3 0.2

Without screening these individuals would have a 3% colorectal cancer risk (30 cases per 1000) and risk of dying of colorectal cancer of 1.1% (11 per 1000).

d. 4% colorectal cancer risk

	Colorectal	Number of	Colorectal	Number of	All-cause		Individuals	Individuals		Risk of c	omplications	
Screening strategy	cancer incidence reduction (%)	prevented colorectal cancer cases	cancer mortality reduction (%)	prevented colorectal cancer deaths		Screening tests	with at least one colonoscopy	with at least two colonoscopies	Perforation and bleeding	Other adverse GI events	Cardiovascular events	Screen procedure related mortality
Biennial FIT	7	3	38	6	0.4	1701	127	42	1.3	1	.7 3	.1 0.07
Annual FIT	11	4	46	7	0.5	2694	175	56	1.7	2	.3 4	.2 0.1
Sigmoidoscopy once-only	25	10	55	8	0.6	1000	278	94	3.2	4	.3 7	.9 0.19
Colonoscopy once-only	32	13	68	10	0.7	1000	1000	116	4.5	6	.1 11	.2 0.27

Without screening these individuals would have a 4% colorectal cancer risk (40 cases per 1000) and a risk of dying of colorectal cancer of 1.5% (15 per 1000).

e. 5% colorectal cancer risk

Screening strategy	Colorectal cancer incidence reduction (%)	Number of prevented colorectal cancer cases	Colorectal cancer mortality reduction (%)	Number of prevented colorectal cancer deaths	All-cause mortality reduction (%)	Screening tests	Individuals with at least one colonoscopy	Individuals with at least two colonoscopies	Risk of complications			
									Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	7	4	38	7	0.5	1688	150	53	1.6	2.	1 3.	.9 0.09
Annual FIT	11	5	46	9	0.6	2650	204	71	2.1	2.	9 5.	.3 0.13
Sigmoidoscopy once-only	26	13	55	10	0.7	1000	343	119	4	5.	4 9.	.9 0.24
Colonoscopy once-only	33	16	68	13	0.9	1000	1000	147	5.6	7.	7 1	.4 0.33

Without screening these individuals would have a 5% colorectal cancer risk (50 cases per 1000) and a risk of dying of colorectal cancer of 1.9% (19 per 1000).

f. 6% colorectal cancer risk

Screening strategy	Colorectal cancer incidence reduction (%)	Number of prevented colorectal cancer cases	Colorectal cancer mortality reduction (%)	Number of prevented colorectal cancer deaths	All-cause mortality reduction (%)	Screening tests	Individuals with at least one colonoscopy	Individuals with at least two colonoscopies	Risk of complications			
									Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	7	4	37	8	0.6	1674	172	64	1.9	2.	.6 4	.7 0.11
Annual FIT	11	7	46	10	0.7	2606	233	86	2.6	3.	.5 6	.4 0.15
Sigmoidoscopy once-only	26	15	55	12	0.9	1000	406	146	4.8	6.	.6 1	12 0.29
Colonoscopy once-only	33	20	68	15	1.1	1000	1000	178	6.7	9.	.1 16	.6 0.4

Without screening these individuals would have a 6% colorectal cancer risk (60 cases per 1000) and a risk of dying of colorectal cancer of 2.2% (22 per 1000).

g. 7% colorectal cancer risk


Screening strategy	Colorectal cancer incidence reduction (%)	Number of prevented colorectal cancer cases	Colorectal cancer mortality reduction (%)	Number of prevented colorectal cancer deaths	All-cause mortality reduction (%)	Screening tests	Individuals with at least one colonoscopy	Individuals with at least two colonoscopies	Risk of complications			
									Perforation and bleeding	Other adverse GI events		Screen procedure related mortality
Biennial FIT	7	5	38	10	0.7	1661	194	75	2.2		3 5.	5 0.13
Annual FIT	11	8	46	12	0.9	2564	260	100	3	4	.1 7.	5 0.18
Sigmoidoscopy once-only	26	19	56	15	1	1000	464	173	5.6	7	6 1	4 0.33
Colonoscopy once-only	33	23	69	18	1.3	1000	1000	210	7.7	10	.4 1	9 0.45

Without screening these individuals would have a 7% colorectal cancer risk (70 cases per 1000) and a risk of dying of colorectal cancer of 2.6% (26 per 1000).

Appendix 5: MISCAN-Colon predictions with lifetime year follow-up stratified for colorectal cancer risk, age and gender


Figure 1: MISCAN-Colon predictions of colorectal cancer mortality reduction, colorectal cancer incidence reduction per 1000 individuals, using FIT, flexible sigmoidoscopy or colonoscopy. Results were stratified for CRC risk. Individuals were followed for a lifetime.

a. Colorectal cancer deaths prevented



b. Colorectal cancer cases prevented


b. Colorectal Cancer Cases Prevented Per 1000 Individuals




Abbreviations: Colo, colonoscopy; CRC, colorectal cancer; FIT, faecal immunochemical test; FS, flexible sigmoidoscopy.

Figure 2: MISCAN-Colon predictions of colorectal cancer mortality reduction, colorectal cancer incidence reduction per 1000 individuals, using FIT, flexible sigmoidoscopy or colonoscopy. Results were stratified for CRC risk and age. Individuals were followed for a lifetime.

a. Colorectal cancer deaths prevented



b. Colorectal cancer cases prevented



Abbreviations: Colo, colonoscopy; CRC, colorectal cancer; FIT, faecal immunochemical test; FS, flexible sigmoidoscopy.